Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer

Cancer Research

Volumn 61, Issue 18, 2001, Pages 6795-6804

  Xie, X ^a   Zhao, X ^a   Liu, Y ^a   Zhang, J ^a   Matusik, R J ^a   Slawin, K M ^a   Spencer, D M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 9; GREEN FLUORESCENT PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER SURVIVAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SUICIDE GENE; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ADENOVIRIDAE; ANDROGEN-BINDING PROTEIN; ANDROGENS; APOPTOSIS; BINDING SITES; CASPASE 9; CASPASES; ENZYME INDUCTION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORGAN SPECIFICITY; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; TUMOR CELLS, CULTURED;

EID: 0035884606     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Virus treatment questioned after gene therapy death
2. Targeting adenovirus
3. Molecular adaptors for vascular-targeted adenoviral gene delivery
4. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
5. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
6. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers
7. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde
8. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
9. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
10. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors
11. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
12. Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines
13. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
14. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice
15. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
16. An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene
17. A small composite probasin promoter confers high level of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo
18. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
19. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 (hK2) promoter
20. Characterization and cloning of rat dorsal prostate mRNAs. Androgen regulation of two closely related abundant mRNAs
21. Regulation of a bifunctional mRNA results in synthesis of secreted and nuclear probasin
22. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene
23. Selective activation of the probasin androgen-responsive region by steroid hormones
24. Prostate cancer in a transgenic mouse
25. Antiviral activity and mechanism of action of ganciclovir
26. Implication of cell kinetic changes during the progression of human prostatic cancer
27. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
28. Developments in suicide genes for pre-clinical and clinical applications
29. Synthetic activation of caspases: Artificial death switches
30. Improved artificial death switches based on caspases and FADD
31. Adenoviral mediated transfer of inducible caspases: A novel "death switch" gene therapeutic approach to prostate cancer
32. Controlling signal transduction with synthetic ligands
33. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
34. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a Phase I clinical trial in malignant mesothelioma
35. Construction of adenovirus vectors through Cre-lox recombination
36. Manipulation of adenovirus vector
37. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene
38. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
39. WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation
40. Creating conditional mutations in mammals
41. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity
42. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease
43. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer
44. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma
45. In situ gene therapy for adenocarcinoma of the prostate: A Phase I clinical trial
46. Gene therapy for prostate cancer: Where are we now?
47. Insulation of a conditionally expressed transgene in an adenoviral vector
48. The hallmarks of cancer
49. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
50. Adenovirus-mediated wild type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
51. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis
52. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer
53. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence
54. Inhibition of death receptor signals by cellular FLIP
55. Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation
56. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
57. Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7
58. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization
59. Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization
60. An induced proximity model for caspase-8 activation
61. Autoproteolytic activation of pro-caspases by oligomerization
62. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
63. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model
64. Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model
65. Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review. Is it indicated?
66. Maximal androgen blockade in prostate cancer: A theory put into practice
67. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines
68. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations